Atlas Trials

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Clinical trial NCT02073123 · COMPLETED

Trial details

NCT number
NCT02073123
Sponsor
NewLink Genetics Corporation
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic MelanomaStage III MelanomaStage IV Melanoma
Start date
2014-07-01
Primary completion
2018-01-17
Enrollment
131

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.